Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Leo Pharma
Pharma
Incyte's JAK cream Opzelura slows while Leo competition looms
Leo Pharma's delgocitinib could shake up the topical JAK market and put pressure on Incyte's approved Opzelura.
Zoey Becker
May 3, 2024 10:53am
Leo Pharma builds its case for JAK inhibitor cream delgocitinib
Jan 24, 2024 10:36am
Leo unveils detailed results on JAK cream win in hand eczema
Oct 13, 2023 11:05am
Leo censured for 'extremely concerning' drug marketing breach
Mar 31, 2023 4:20am
Leo Pharma scores in phase 3 trial for JAK inhibitor cream
Feb 13, 2023 3:05pm
Leo's JAK inhibitor cream posts positive results for hand eczema
Dec 6, 2022 10:02am
